US 11,939,352 B2
Potent aromatase inhibitors through fungal transformation of anti-cancer drug testolactone: an approach towards treatment of breast cancer
Muhammad Iqbal Choudhary, Karachi (PK); Atia-tul Wahab, Karachi (PK); Mahwish Siddiqui, Karachi (PK); Nimra Naveed Shaikh, Karachi (PK); Sammer Yousuf, Karachi (PK); and Atta-ur Rahman, Karachi (PK)
Filed by Muhammad Iqbal Choudhary, Karachi (PK); Atia-tul Wahab, Karachi (PK); Mahwish Siddiqui, Karachi (PK); Nimra Naveed Shaikh, Karachi (PK); Sammer Yousuf, Karachi (PK); and Atta-ur Rahman, Karachi (PK)
Filed on Feb. 17, 2021, as Appl. No. 17/177,209.
Prior Publication US 2021/0230214 A1, Jul. 29, 2021
Int. Cl. C07D 311/78 (2006.01); A61K 31/366 (2006.01); A61K 31/585 (2006.01); A61P 35/00 (2006.01); C07D 493/04 (2006.01); C07J 73/00 (2006.01)
CPC C07J 73/003 (2013.01) [A61P 35/00 (2018.01)] 2 Claims
 
1. A testolactone derivative selected from the group consisting of 7β-hydroxy-3-oxo-13,17-seco-5β-androsta-1-eno-17,13α-lactone (2), 3α,11β-dihydroxy-13,17-seco-5β-androsta-17,13α-lactone (3), 4β,5β-epoxy-3β-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (4), and 4β,5β-epoxy-3α-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (5) and a pharmaceutically acceptable salt thereof.